Can I read The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy on EtoBox?

The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy by Spasenija Savic; Inti Zlobec; George N. Thalmann; Daniel Engeler; Martina Schmauss; Kurt Lehmann; Gianfranco Mattarelli; Tobias Eichenberger; Peter Dalquen; Peter Spieler; René Schoenegg; Thomas C. Gasser; Tullio Sulser; Thomas Forster; Tobias Zellweger; Roberto Casella; Lukas Bubendorf is a scholarly article available to read on EtoBox.

What is The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy about?

## Abstract Molecular markers reliably predicting failure or success of Bacillus Calmette‐Guérin (BCG) in the treatment of nonmuscle‐invasive urothelial bladder cancer (NMIBC) are lacking. The aim of our study was to evaluate the value of cytology and chromosomal aberrations detected by fluorescence __in situ__ hybridization (FISH) in predicting failure to BCG therapy. Sixty‐eight patients with NMIBC were prospectively recruited. Bladder washings collected before and after BCG instillation were analyzed by conventional cytology and by multitarget FISH assay (UroVysion®, Abbott/Vysis, Des Plaines, IL) for aberrations of chromosomes 3, 7, 17 and 9p21. Persistent and recurrent bladder cancers were defined as positive events during follow‐up. Twenty‐six of 68 (38%) NMIBC failed to BCG. Both positive post‐BCG cytology and positive post‐BCG FISH were significantly associated with failure of BCG (hazard ratio (HR)= 5.1 and HR= 5.6, respectively; __p__ < 0.001 each) when compared to those with negative results. In the subgroup of nondefinitive cytology (all except those with unequivocally positive cytology), FISH was superior to cytology as a marker of relapse (HR= 6.2 and 1.4, respectivel

Author

Spasenija Savic; Inti Zlobec; George N. Thalmann; Daniel Engeler; Martina Schmauss; Kurt Lehmann; Gianfranco Mattarelli; Tobias Eichenberger; Peter Dalquen; Peter Spieler; René Schoenegg; Thomas C. Gasser; Tullio Sulser; Thomas Forster; Tobias Zellweger; Roberto Casella; Lukas Bubendorf

Publisher

John Wiley and Sons; Wiley (John Wiley & Sons); John Wiley & Sons Inc.; Wiley; Research Square; Test accounts (ISSN 0020-7136)

Published

2009

Language

EN